Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts

British Journal of Cancer

Volumn 76, Issue 6, 1997, Pages 700-704

  Pace, P ^a   Jarman, M ^b   Phillips, D ^b   Hewer, A ^b   Bliss, J ^b   Coombes, R C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antioestrogen; DNA adducts; N methylnitrosourea induced mammary tumour

Indexed keywords

ANTIESTROGEN; IDOXIFENE; METHYLNITROSOUREA; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOGENESIS; CONTROLLED STUDY; DNA ADDUCT; DRUG POTENCY; FEMALE; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030750807     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.449     Document Type: Article

References (20)

1. Bruning PF (1992) Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding Phase II trial. Eur J Cancer 28A: 1404-1407
2. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M and Coombes RC (1991) Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antioestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851-5858
3. Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R and Jarman M (1995) Idoxifene: report of a Phase I study in patients with metastatic breast cancer. Cancer Res 55: 1070-1074
4. Early Breast Cancer Trials Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal cytotoxic and immune therapy: 133 randomized trials involving 331,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15
5. Gupta RC (1984) Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc Natl Acad Sci USA 81: 6943-6947
6. Haynes BP, Parr IB, Griggs LJ and Jarman M (1991) Metabolism and pharmacokinetics of pyrrolidino-4-iodotamoxifen in the rat. Breast Cancer Res Treat 19: 174
7. Jordan VC (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110: 507-517
8. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M and Foster AB (1989) Derivatives of tamoxifen. Dependence of antioestrogenicity on the 4-substituent. J Med Chem 32: 2527-2533
9. McCague R, Parr IB, Leclercq G, Leung O-T and Jarman M (1990) Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol 39: 1459-1465
10. 5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of activation of tamoxifen to a liver carcinogen. Carcinogenesis 15: 1487-1492
11. Phillips DH, Carmichael PL, Hewer A, Cole KJ and Poon GK (1994 b) Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54: 5518-5522
12. Poon GK, Walter B, Lonning PE, Horton MN and McCague R (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 23: 377-382
13. Potter GA, McCague R and Jarman M (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 15: 43462
14. Powles TJ, Hardy JR, Ashley SE, Farrington GH, Cosgrove D, Davey JR, Dowsett M, McKinna JA, Wash AG, Sinnett HD, Tillyer CR and Treleaven JG (1989) A pilot trial to evaluate the acute toxicology and feasibility of tamoxifen for prevention of breast cancer. B J Cancer 60: 126-131
15. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB and McKinna JA (1990) Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital Pilot program. Eur J Cancer 26: 680-684
16. Scholl SM, Huff KK and Lippman ME (1983) Antioestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 113: 611-617
17. Seoud M, A-F, Johnson J and Weed JC (1993) Gynecologic tumours in tamoxifen-treated women with breast cancer. Obstet Gynecol 82: 165-169
18. Vogel CL, Shemano I, Schoenfelder J, Gams RA and Green MR (1993) Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 11: 345-350
19. Wakeling AE, Dukes M and Bowler J (1991) A potent specific pure anti-oestrogen with clinical potential. Cancer Res 51: 3867-3873
20. White INH, De Matteis F, Davies A, Smith LL, Croftton-Sleigh C, Venitt S, Hewer A and Phillips DH (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197-2203